1. Khaodee W, Xiyuan G, Han MTT, Tayapiwatana C, Chiampanichayakul S, Anuchapreeda S, Cressey R. Transcriptomic analysis of glucosidase II beta subunit (GluIIß) knockout A549 cells reveals its roles in regulation of cell adhesion molecules (CAMs) and anti-tumor immunity. BMC Genomics 2024;25(1):82. doi: 10.1186/s12864-023-09888-z.

2. Bekker A, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, Cressey R, Nielsen J, Capparelli EV, Lallemant M, Cotton MF, Cressey TR; PETITE-ABC/3TC-LPVr Study Team. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial. Lancet HIV 2024;11(2):e86-e95. doi: 10.1016/S2352-3018(23)00289-8.

3. Han MTT, Pornprasert S, Saeteng S, Tantraworasin A, Siwachat S, Thuropathum P, Chewaskulyong B, Cressey R. Small RNA deep sequencing of circulating RNAs discovers a unique panel of microRNAs as feasible and reliable biomarkers of non-Small cell lung cancers in Northern Thailand. Asian Pac J Cancer Prev 2023;24(10):3585–98.

4. Liegeon G, Ngo-Giang-Huong N, Salvadori N, Bunpo P, Cressey R, Achalapong J, Kanjanavika P, Patamasingh Na Ayudhaya O, Prommas S, Siriwachirachai T, Sabsanong P, Yves Mary J, Jourdain G. Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus. J Antimicrob Chemother 2022;77(4):1111-8.

5. Bekker A, Rabie H, Salvadori N, du Toit S, Than-In-At K, Groenewald M, Andrieux-Meyer I, Kumar M, Cressey R, Nielsen J, Capparelli E, Lallemant M, Cotton MF, Cressey TR. PETITE Study Team. Pharmacokinetics and safety of the abacavir/lamivudine/lopinavir/ritonavir fixed-dose granule formulation (4-in-1) in neonates: PETITE study. J Acquir Immune Defic Syndr 2022;89(3):324-31.

6. Niu X, Kubiak RW, Siriprakaisil O, Klinbuyaem V, Sukrakanchana P, Cressey R, Okochi H, Gandhi M, Cressey TR, Drain PK. Tenofovir-Diphosphate in dried blood spots versus tenofovir in urine/plasma for oral preexposure prophylaxis adherence monitoring. Open Forum Infect Dis 2022;9(8):ofac405. doi.org/10.1093/ofid/ofac405.

7. Chuathong W, Phomsakha Na Sakonnakhon W, Lilakhon A, Devahastin Na Ayudhaya N, Khaodee W, Tima S, Intasai N, Chaiwongsa R, Chiampanichayakul S, Punturee K, Cressey R. Beneficial effects of macaroni made with resistant starch type 4 from unripe banana and turmeric extract on blood clinical chemistry and gut microbiota of healthy rats. J Food Nutr Res 2021;9(7):329-41.

8. Cressey TR, Siriprakaisil O, Kubiak RW, Klinbuayaem V, Sukrakanchana PO, Quame-Amaglo J, Okochi H, Tawon Y, Cressey R, Baeten JM, Gandhi M, Drain PK. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Int J Infect Dis 2020;97(-):365-70.

9. Drain PK, Kubiak RW, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Sukrakanchana PO, Tanasri S, Punyati P, Sirirungsi W, Cressey R, Bacchetti P, Okochi H, Baeten JM, Gandhi M, Cressey TR. Urine tenofovir concentrations correlate with plasma and relates to TDF adherence: A randomized directly-observed pharmacokinetic trial (TARGET Study). Clin Infect Dis 2020;70(10):2143-51.